



Targeting MDSC in Cancer Therapy

Guest Editor:

Prof. Dr. Sherven Sharma

Department of Medicine, UCLA
Lung Cancer Research Program,
David Geffen School of Medicine
at UCLA, Los Angeles, CA, USA

Deadline for manuscript
submissions:

closed (31 December 2019)

Message from the Guest Editor

Cancer program cellular infiltrates sustain a dysregulated inflammation that is hypo-responsive to the cancer. Contributing to the cellular inflammatory infiltrates are myeloid-derived suppressor cells (MDSC) that negatively modulate immune responses and promote tumor angiogenesis, drug resistance, tumor progression, and metastases. MDSCs are a heterogeneous population of immature myeloid cells consisting of myeloid progenitors and precursors of macrophages, granulocytes, and dendritic cells (DC). Increases in the number of MDSCs evoke strong natural suppressive activity in cancer. MDSCs suppress T cell and NK cell activity. Progressive tumor growth is associated with the down-regulation of T cell responses, and MDSCs are involved in negative immunoregulatory mechanisms. Although cancer immunotherapy offers an attractive therapeutic option, activation of the immune system alone is not sufficient for antitumor activity. Targeting pathways of immune activation and mechanisms of immune suppression presents an attractive therapeutic opportunity to combat cancer. Targeting MDSCs may improve cancer immunotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI